SCHEMBL8070549

SCHEMBL8070549

Cn1c(=O)c2c(ncn2CCCCCCCCCC2CO2)n(C)c1=O

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ADORA2B P29275 9/20 0.64
▸ RXFP1 Q9HBX9 2/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ LMNA P02545 2/20 0.56
▸ MAPT P10636 1/20 0.56
▸ TSHR P16473 1/20 0.55
▸ HTR7 P34969 1/20 0.54
▸ HTR6 P50406 1/20 0.54
▸ ADORA2A P29274 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9293746 1.00 ADORA2B (0.64) ADORA2BRXFP1MAPK1KMT2ALMNA
SCHEMBL9294688 1.00 ADORA2B (0.64) ADORA2BRXFP1MAPK1KMT2ALMNA
SCHEMBL9293797 1.00 ADORA2B (0.64) ADORA2BRXFP1MAPK1KMT2ALMNA
SCHEMBL9294484 1.00 ADORA2B (0.64) ADORA2BRXFP1MAPK1KMT2ALMNA
SCHEMBL9293917 0.99 ADORA2B (0.66) ADORA2BRXFP1MAPK1KMT2ALMNA
SCHEMBL9294500 0.88 ADORA2A (0.59) ADORA2BRXFP1MAPK1KMT2AADORA2A
SCHEMBL16121000 0.85 ADORA2B (0.85) ADORA2BRXFP1MAPK1LMNAMAPT
SCHEMBL16120989 0.85 ADORA2B (0.85) ADORA2BRXFP1MAPK1LMNAMAPT
SCHEMBL16120982 0.85 ADORA2B (0.85) ADORA2BRXFP1MAPK1LMNAMAPT
SCHEMBL16120999 0.85 ADORA2B (0.85) ADORA2BRXFP1MAPK1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6121270-A N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI CELL THERAPEUTICS, INC. (US) 2000-09-19 — — US disclosed
US-5866576-A COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. CELL THERAPEUTICS, INC. (US) 1999-02-02 — — US disclosed
Send feedback